We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.00 | 0.20% | 1,523.00 | 1,522.00 | 1,524.00 | 1,540.00 | 1,496.00 | 1,540.00 | 206,965 | 15:32:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.09B | 2M | 0.0148 | 1,031.08 | 2.06B |
TIDMINDV
RNS Number : 6702H
Indivior PLC
16 November 2018
Indivior PLC - Director Declaration
Indivior PLC confirms that Daniel Tassé, Senior Independent Director, will be appointed Chief Executive Officer of DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq: DBVT), a clinical stage biopharmaceutical company, with effect from November 29, 2018.
There have been no other changes to the information set out in LR 9.6.13R (2) to LR 9.6.13R (6) in respect of Mr Tassé.
This announcement is made in accordance with Listing Rule 9.6.14.
Kathryn Hudson
Company Secretary
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RDNFKADQPBDDFDD
(END) Dow Jones Newswires
November 16, 2018 10:52 ET (15:52 GMT)
1 Year Indivior Chart |
1 Month Indivior Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions